Back to pharmacy menu


Certain oral oncology medications have the first six fills limited to a 14 or 15 day supply per fill. After six fills, the prescription may be filled for up to a 30 day supply per fill. Copays will be prorated so that participants will only pay half of a copay for the two-week fills.

The purpose of this program is to minimize waste of expensive medications.The medications included in this program have a high rate of discontinuation due to adverse effects. Many patients who begin taking one of these medications discontinue the medication within the first two weeks.

Below are the medications included in the Oncology Split Fill program –

  • Alecensa® (alectinib HCl)
  • Afinitor®  (everolimus)
  • Bosulif®  (bosutinib)
  • Imbruvica®  (ibrutinib)
  • Inlyta®  (axitinib)
  • Iressa® (gefitinib)
  • Jakafi® (ruxolitinib)
  • Lynparza® (olaparib)
  • Nexavar® (sorafenib tosylate)
  • Sprycel® (dasatinib)
  • Sutent® (sunitinib malate)
  • Tagrisso® (osimertinib mesylate)
  • Tarceva® (erlotinib HCl)
  • Tasigna® (nilotinib HCl)
  • Votrient® (pazopanib HCl)
  • Xalkori® (crizotinib)
  • Xtandi® (enzalutamide)
  • Zelboraf® (vemurafenib)
  • Zykadia® (ceritinib)